Tagrisso 80 Mg Tablets

Tagrisso 80 mg Tablets is a targeted therapy medication containing Osimertinib, designed for the treatment of non-small cell lung cancer (NSCLC) in adults with specific epidermal growth factor receptor (EGFR) mutations. This third-generation EGFR inhibitor effectively impedes cancer cell proliferation, leading to tumor size reduction and hindrance of metastasis.

Key Features:

• Active Ingredient: Each film-coated tablet comprises 80 mg of Osimertinib.
• Indications:
  • First-line Treatment: Suitable for patients with metastatic NSCLC exhibiting specific EGFR mutations.
  • Post-Surgical (Adjuvant) Therapy: Administered following complete tumor resection to minimize recurrence risk.
  • Administration: Oral intake of one tablet daily, with or without food, at a consistent time each day. Swallow the tablet whole; if swallowing is challenging, dissolve it in still water and consume immediately.
• Benefits:
  • Specifically targets cancer cells with EGFR mutations, preserving healthy cells and reducing adverse effects compared to traditional chemotherapy.
  • Demonstrated to extend progression-free survival in patients with EGFR-mutated NSCLC.
  • Convenient once-daily dosing enhances patient compliance and quality of life.
  • Effective in managing brain metastases due to its ability to penetrate the blood-brain barrier.
• Common Side Effects:
  • Diarrhea
  • Skin rash
  • Fatigue
  • Nausea and vomiting
  • Elevated liver enzymes
  • Rare cases of pneumonitis (lung inflammation)

Precautions:

• Pregnancy and Breastfeeding: Tagrisso can harm an unborn child; effective contraception is advised during treatment and for a specified period afterward. Breastfeeding is not recommended during therapy and for two weeks post-treatment.
• Pre-existing Conditions: Inform your doctor if you have a history of lung inflammation (interstitial lung disease), heart problems, or eye issues before starting Tagrisso.
• Drug Interactions: Disclose all medications, including over-the-counter drugs and supplements, to your healthcare provider to avoid potential interactions.

Note: Regular monitoring through imaging and blood tests is essential to evaluate treatment efficacy and manage any potential side effects. Consult your healthcare provider for personalized guidance and to address any concerns during your treatment journey.